Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH schizophrenia trials network study

Clinical Schizophrenia and Related Psychoses

Volumn 1, Issue 1, 2007, Pages 69-72

  Stroup, T Scott ^a   McEvoy, Joseph P ^b   Swartz, Marvin S ^b   Hamer, Robert M ^a   Perkins, Diana O ^a   Lieberman, Jeffrey A ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BEHAVIOR THERAPY; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIETARY INTAKE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 34548085026     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.1.1.6     Document Type: Article

References (12)

1. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161(8):1334-49.
2. Meyer JM, Nasrallah HA, editors. Medical illness and schizophrenia. Washington (DC):American Psychiatric Press, Inc; 2003.
3. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45(1-2):21-28.
4. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51(6):931-38.
5. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29(1):15-31.
6. McEvoy JP, Meyer J, Goff D, Nasrallah H, Davis SM, Sullivan L, Meltzer HY, Stroup TS, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: results from CATIE and comparison with national estimates from NHANES III. Schizophr Res 2005;80(1):19-32.
7. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161(11):1413-19.
8. Hirsch GA, Vaid N, Blumenthal RS. Perspectives: the significance of measuring non-HDL-cholesterol. Prev Cardiol 2002;5(3):156-59.
9. Simpson S, Potkin SG. Switching from risperidone to ziprasidone. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-19; Washington, D.C.
10. Casey DE, Saha A, Ali M, et al. Switching to aripiprazole monotherapy. 23rd Collegium Internationale Neuropsychopharmacologicum Congress; 2002 Jun 23-27; Montreal, Canada.
11. Daniel DG, Lieberman J, Birnbaum R. Improvements in markers of health status 6 weeks after switching from olanzapine to ziprasidone. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-19; Washington, D.C.
12. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2005;66(2):205-12.